Contact Us | Site Index | Legal

Press Releases

PGNX - (NASDAQ)
$5.11   - 0.22
Jul 2, 2009
4:03 PM ET
News Feeds
= Add Release to Briefcase
All Releases
View Summary Progenics Announces Initiation of RELISTOR Clinical Trials in Japan by Ono Pharmaceutical
Jun 8, 2009
PDF 16.6 KB Add to Briefcase
View Summary Progenics Provides Update on Hepatitis C Program
Jun 8, 2009
PDF 13.1 KB Add to Briefcase
View Summary Progenics Announces First Quarter Financial Results
May 11, 2009
PDF 21.3 KB Add to Briefcase
View Summary Phase 3 Clinical Study of RELISTOR Presented at American Pain Society Meeting Showed Positive Activity for the Treatment of Opioid-Induced Constipation in Chronic,Non-Cancer Pain Patients
May 7, 2009
PDF 22.7 KB Add to Briefcase
View Summary Progenics Pharmaceuticals Reports Fourth Quarter and Year-End Results and Corporate Update
Mar 13, 2009
PDF 23.6 KB Add to Briefcase
View Summary Progenics Selects Subcutaneous Form of PRO 140, A Novel HIV Antibody Therapy, For Further Development
Feb 10, 2009
PDF 75.3 KB Add to Briefcase
View Summary Progenics Appoints Peter J. Crowley as Independent Board Member
Feb 4, 2009
PDF 13.2 KB Add to Briefcase
View Summary Announcement by Progenics Pharmaceuticals under Nasdaq Marketplace Rules
Dec 11, 2008
PDF 12.5 KB Add to Briefcase
View Summary Wyeth and Progenics Announce Positive Outcome of Phase 3 Clinical Study of Subcutaneous RELISTOR for Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain
Nov 26, 2008
PDF 19.7 KB Add to Briefcase
View Summary Progenics Announces Wyeth Has Received Relistor Approval in Australia
Nov 17, 2008
PDF 14.3 KB Add to Briefcase
View Summary Progenics Reports Third Quarter 2008 Financial Results and Corporate Updates
Nov 10, 2008
PDF 20.1 KB Add to Briefcase
View Summary Progenics Selects Small-Molecule Hepatitis C Drug Candidate for Clinical Development
Nov 4, 2008
PDF 14.7 KB Add to Briefcase
View Summary Progenics Reports Positive Interim Phase 2 Results for Two Dosage Forms 0f Novel HIV Therapy PRO 140
Oct 26, 2008
PDF 227.1 KB Add to Briefcase
View Summary Progenics Pharmaceuticals and Ono Pharmaceutical Announce Agreement to Develop and Commercialize RELISTOR in Japan
Oct 16, 2008
PDF 16.2 KB Add to Briefcase
View Summary Progenics Announces Progress and Presentations in HIV Therapy Program
Oct 2, 2008
PDF 18.0 KB Add to Briefcase
View Summary Progenics Initiates Phase 1 Clinical Study of Targeted Therapy for Prostate Cancer
Sep 8, 2008
PDF 18.7 KB Add to Briefcase
View Summary Progenics Pharmaceuticals Reports Second Quarter 2008 Results
Aug 8, 2008
PDF 21.7 KB Add to Briefcase
View Summary Wyeth and Progenics Receive Approval from European Commission for RELISTOR for Opioid-Induced Constipation in Advanced Illness Patients
Jul 3, 2008
PDF 18.4 KB Add to Briefcase
View Summary New England Journal Of Medicine Publishes Results From A Relistor Phase 3 Clinical Study
May 28, 2008
PDF 20.0 KB Add to Briefcase
View Summary Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations
May 22, 2008
PDF 20.5 KB Add to Briefcase
Showing 1-20 of 88 releases Page: 1 2 3 4 5  See Next 20